| abstract |
The present invention relates to the sequential administration of a cytotoxic agent followed by an IGF1R antagonist (eg, antibody) for the treatment of hyperproliferative disorders, including cancer. The invention also relates to hyperproliferative disorders mediated by elevated expression or activity of insulin-like growth factor I receptor in a subject, or elevated expression of IGF-1, or elevated expression of IGF-II (eg, A method of treating or preventing cancer, comprising administering to a subject a therapeutically effective amount of a cytotoxic anticancer chemotherapeutic agent (eg, irinotecan or cyclophosphamide), followed by therapy A method is provided comprising administering to the subject a top effective amount of an IGF1R inhibitor (eg, an anti-IGF1R antibody). |